Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Otsuka Plans $2.8 Billion IPO To Feed Global Expansion

This article was originally published in The Pink Sheet Daily

Executive Summary

Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.

You may also be interested in...

Otsuka Looks To IPO To Fund Overseas Expansion

Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year

BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability

New claim puts the atypical antipsychotic on par with J&J's Risperdal.

Bristol-Myers Squibb and Otsuka Stabilize Their Bases

The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced in April appear to be a win for both sides. They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement's terms in consideration of each partner's current needs. At the same time, they recognize that the key product involved, the antipsychotic medication Abilify, is reaching maturity.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts